Combination of beta-2-adrenergic receptor agonists and glp-1 receptor agonists for use in treating hyperglycaemia
AssigneeAtrogi AB
InventorsTore Bengtsson, Benjamin Pelcman, Anastasia Kalinovich
Life of this patent
Estimating the term…
Abstract
There is provided herein a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prophylaxis of hyperglycaemia or a disorder characterized by hyperglycaemia, wherein the treatment and/or prophylaxis further comprises administration of: (a) insulin or a therapeutic insulin derivative; or (b) a therapeutic agent stimulating the release of insulin.
Claims14
A β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prophylaxis of hyperglycaemia or a disorder characterized by hyperglycaemia, wherein the treatment and/or prophylaxis further comprises administration of:
- (a) insulin or a therapeutic insulin derivative;
- or
- (b) a therapeutic agent stimulating the release of insulin.
A compound that is:
- (a) insulin or a therapeutic insulin derivative;
- or
- (b) a therapeutic agent stimulating the release of insulin
- for use in the treatment and/or prophylaxis of hyperglycaemia or a disorder characterized by hyperglycaemia, wherein the use further comprises administration of a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof.
A combination of a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, and a compound that is:
- (a) insulin or a therapeutic insulin derivative;
- or
- (b) a therapeutic agent stimulating the release of insulin
- for use in the treatment and/or prophylaxis of hyperglycaemia or a disorder characterized by hyperglycaemia.
A method for the treatment and/or prophylaxis of hyperglycaemia or a disorder characterized by hyperglycaemia comprising:
- (i) administration of a therapeutically effective amount of
- (a) insulin or a therapeutic insulin derivative;
- or
- (b) a therapeutic agent stimulating the release of insulin, and
- (ii) administration of a therapeutically effective amount of a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof,
- to a patient in need thereof.
A pharmaceutical formulation comprising:
- (I) a compound that is
- (a) insulin or a therapeutic insulin derivative;
- or
- (b) a therapeutic agent stimulating the release of insulin, and
- (II) a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof,
- and optionally one or more pharmaceutically acceptable excipient.
A combination or kit-of-parts comprising components:
- (A) a pharmaceutical formulation comprising a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, optionally in admixture with one or more pharmaceutically acceptable excipient, and
- (B) a pharmaceutical formulation comprising insulin or a therapeutic insulin derivative, or a therapeutic agent stimulating the release of insulin, optionally in admixture with one or more pharmaceutically acceptable excipient,
- wherein components (A) and (B) are each provided in a form that is suitable for administration in conjunction with the other.
Dependencies are inferred from the claim text.